

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Clinical Practice – Surveillance Programme

Clinical guideline

CG32: Nutrition support in adults - oral nutrition support, enteral tube feeding and parenteral nutrition

Publication date

February 2006

8-year surveillance report for GE (post consultation)

May 2014

Previous review dates

2-year review: 2008 (no update)

5-year review: 2011 (no update)

Key findings

| | | | Potential impact on guidance | |
|---|--------------|-----------------|------------------------------|---------------------|
| | | | Yes | No |
| Evidence identified from literature search | | | | ✓ |
| Feedback from Guideline Development Group | | | | ✓ |
| Anti-discrimination and equalities considerations | | | | ✓ |
| No update | Rapid update | Standard update | Transfer to static list | Change review cycle |
| ✓ | | | | |

Surveillance recommendation

GE is asked to consider the proposal to not update the Nutrition support in adults guideline at this time. The surveillance review proposal was consulted on for two weeks.

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Clinical Practice – Surveillance Programme

8-year surveillance review of CG32: Nutrition support in adults - oral nutrition support, enteral tube feeding and parenteral nutrition

Background information

Guideline issue date: February 2006

2-year review: 2008 (no update)

5-year review: 2011 (no update)

NCC: Acute Care

Main conclusions of previous surveillance reviews

1. CG32 was previously reviewed for update in 2008 and 2011; at both review points no new evidence was identified that would change the direction of guideline recommendations.
2. In the 2011 review, the area of “immunonutrition” which is outside of the guideline scope was identified as an emerging topic and focussed searches were conducted to identify studies. However, it was felt that the available evidence was not sufficiently conclusive to merit inclusion of immunonutrition into the guideline at that time.

Eight-year surveillance review

3. An Evidence Update was produced for the guideline in 2013 and this was used as one source of evidence for the review proposal. The Evidence Update concluded that the new evidence identified since the review in 2011 did not have any impact on the guideline recommendations.

4. For the 8-year Surveillance Review, a search to identify randomised controlled trials and systematic reviews was carried out for articles published between 01 March 2013 (the end of the search period for the Evidence Update) and 30 September 2013 and relevant abstracts were assessed.
5. Clinical feedback on the guideline was obtained from members of the GDG through a questionnaire; six responses were received.
6. No new evidence was identified for any section of the guideline that may impact on current recommendations or necessitate expansion of the scope to include new topic areas.

Summary of stakeholder feedback

7. Stakeholders were consulted about the following proposal over a two week consultation period:

Through the 8-year surveillance review of CG 32 no new evidence was identified which may potentially change the direction of current guideline recommendations or may necessitate an expansion of the scope. The proposal is not to update the guideline at this time.

8. Six stakeholders commented on the surveillance review proposal during the two-week consultation period (see [Appendix 1](#)).
9. Four stakeholders agreed with the review proposal to not update the guideline at this time, one stakeholder did not state a definitive decision and one stakeholder did not agree.
10. The stakeholder that disagreed with the surveillance review proposal suggested that the use of Cortrak, a bedside device that uses an electromagnetic sensor to track nasogastric and post pyloric tubes during placement should be recommended in the guideline. They also provided a draft journal paper (comprising a narrative review of observational studies) to support their case. However, as this paper is unpublished we are unable to consider it at this surveillance point.
11. No comments were provided by any stakeholder on equality issues or areas excluded from the original scope.

Ongoing trials

12. Two ongoing trials were identified. The PROWL project in Australia, on the effectiveness of a composite nutritional intervention (a nutritional screening tool, the provision of food supplements at ward level, and a red tray system to identify those patients requiring help with eating and drinking) to reduce malnutrition in hospitalised adult patients; completion date is not known, the study protocol has been published

13. The other trial is the UK NIHR HTA-funded CALORIES trial comparing the clinical and cost-effectiveness of early nutritional support in critically ill patients via the parenteral versus the enteral route, is still ongoing and is due for completion in December 2015

Anti-discrimination and equalities considerations

14. None identified.

Implications for other NICE programmes

15. This guideline relates to a published quality standard on Nutrition support in adults (QS24)

16. A quality standard on Nutrition in hospital, including young people has been referred; a provisional start date is yet to be agreed.

17. The guideline will remain on the active surveillance list.

Conclusion

18. Through the 8-year surveillance review of CG 32 no new evidence was identified for any section of the guideline that may impact on current recommendations or necessitate expansion of the scope to include new topic areas.

Surveillance recommendation

19. GE is asked to consider the proposal to not update the Nutrition support in adults guideline at this time.

Mark Baker – Centre Director
Sarah Willett – Associate Director
Khalid Ashfaq – Technical Analyst

Centre for Clinical Practice
May 2014

Appendix 1 - Consultation comments and response

| Stakeholder | Do you agree that the guidance should not be updated? | Comments on equality issues or areas excluded from the original scope | Comments If you disagree please explain why | Response |
|--------------------------------------|---|--|---|--|
| Lancashire Care NHS Foundation Trust | Agree | | | Thank you. |
| NHS England | I am in agreement with the suggestion that there is no new evidence indicating that this guidance needs review at this time | | | Thank you for your comment. |
| Department of Health | No substantive comments to make, regarding this consultation | | | Thank you. |
| Royal College of Physicians | The RCP is grateful for the opportunity to comment and supports the NICE proposal not to update at this time. | | | Thank you for your comment. |
| The Royal College of Nursing | Agree Support the stance that there is no requirement for an update of this guidance at present | None | | Thank you for your comment. |
| CORPAK MedSystems UK | Disagree - sections 1.7 of Clinical Guideline 32 (especially 1.7.17) | We believe that the exclusion of Cortrak from the guidance results in inequality between centres (some hospitals use Cortrak, others | <u>PLEASE ALSO SEE ATTACHMENTS. PLEASE REGARD THE DRAFT</u> | Thank you for your comment and for providing the draft of the paper on the Cortrak |

| Stakeholder | Do you agree that the guidance should not be updated? | Comments on equality issues or areas excluded from the original scope | Comments If you disagree please explain why | Response |
|-------------|---|--|---|---|
| | | <p>rely on blind placement), resulting in 'postcode' differences in outcomes and risk. In addition, the exclusion of Cortrak incurs avoidable costs, undermines efficacy and places patients at avoidable risk. (It is worth noting that many patients requiring enteral feed are unable to give informed consent. Arguably, this places HCP under ethical and moral obligations to minimise risk.)</p> <p>Early initiation of enteral nutrition reduces, for example: gastrointestinal damage; infections; mortality among mechanically ventilated patients; and hospital stay. (We have attached an initial draft of a narrative review intended for publication in a peer-review journal, which gives full references. An updated version of this 'work in progress' will form part of any formal NICE submission.) Increasing evidence indicates that the misplacement of conventional nasoenteric tubes (NETs) is relatively common, associated with serious complications, and incurs avoidable costs and consequences.</p> <p>We believe that the weight of evidence (see attached files and the draft review attached) now shows that the Cortrak enteral access system improves clinical and economic outcomes in patients requiring NETs. As a result, we believe that the evidence supports</p> | <p><u>PAPER AS CONFIDENTIAL AS THIS IS A WORK IN PROGRESS AND WILL BE SUBMITTED TO A PEER REVIEW JOURNAL.</u></p> | <p>enteral access system.</p> <p>The harm caused by misplaced nasogastric feeding tubes is always a concern, however, as this paper is unpublished we are unable to consider it at this surveillance point.</p> |

| Stakeholder | Do you agree that the guidance should not be updated? | Comments on equality issues or areas excluded from the original scope | Comments If you disagree please explain why | Response |
|-------------|---|---|--|----------|
| | | <p>reconsideration of sections 1.7 of Clinical Guideline 32 (especially 1.7.17) and NHS England guidance.</p> <p>Briefly, feeding through a misplaced NET can prove fatal and rigid or fine bore NETs can cause pneumothorax and other complications. Increasing evidence, including new analyses in the attached review, suggest that spontaneous reports and many healthcare professionals (HCP) underestimate these risks.</p> <p>HCPs should use one or more methods to assess the position of NETs. However, conventional techniques have limitations. Although widely used and advocated by NHS England, pH measurements may be misleading in some patients, such as those taking proton pump inhibitors and requiring continuous enteral feeds. In addition, difficulty in obtaining aspirate can delay feeding, hydration or the delivery of medications, which potentially compromises outcomes.</p> <p>When NET placement is in doubt based on pH, chest radiographs are performed. However, radiological misinterpretation is the most common cause of NETs-related incidents reported to the NPSA. Moreover, inadvertent bronchial intubation may cause pulmonary trauma between the NET insertion and x-ray confirmation of the inappropriate placement.</p> | | |

| Stakeholder | Do you agree that the guidance should not be updated? | Comments on equality issues or areas excluded from the original scope | Comments If you disagree please explain why | Response |
|-------------|---|--|--|----------|
| | | <p>Further x-rays may be required as NETs can migrate by coughing, retching, vomiting or movement.</p> <p>Radiographs can delay the start of enteral feeding, hydration and medication. Currently, approximately 50% of critically ill patients do not reach caloric targets with nasogastric feeding. Eliminating delays, such as those associated with x-ray, helps patients start tube feeding more rapidly and potentially increases the proportion that attain targets.</p> <p>Cortrak is a bedside system that uses an electromagnetic sensor to track the NET during placement. Cortrak can be used in diverse settings (eg acute ward, intensive care and out-patient clinics) for a wide range of indications (corpakmedsystemsuk.com/Learning_Center/learning-center.html).</p> <p>Several studies compared NET placement using Cortrak with chest x-ray (table 1 [table numbers refer to the accompanying paper]). The median proportion of correct placements using Cortrak was 100%. Indeed, in clinical studies, Cortrak virtually eliminates misplacement (table 2). Cortrak detects when the NET enters the lung allowing immediate repositioning and avoids additional radiogram if a HCP suspects NET migration. Our analysis</p> | | |

| Stakeholder | Do you agree that the guidance should not be updated? | Comments on equality issues or areas excluded from the original scope | Comments If you disagree please explain why | Response |
|-------------|---|--|--|----------|
| | | <p>suggests that 2.2% of NETs positioned with blind placements enter the pulmonary system, suggesting an estimated 5962 potential never events annually.</p> <p>Avoiding x-rays saves resources (table 4), even when an initial radiograph is mandated. Cortrak reduces the time to the start of enteral nutrition by 60% (15.2 hours), compared to blind placement (p=0.05-0.01; table 3). Furthermore, HCPs can insert NETs more rapidly with Cortrak than blind placement.</p> <p>As Cortrak virtually eliminates NET misplacement, iatrogenic pneumothorax was not seen in the clinical studies (p=0.005 versus blind placement). We estimate that a trust performing 1500 NET insertions a year using blind placements would manage about seven iatrogenic pneumothoraces (table 6). As a first approximation, a pneumothorax costs an estimated £3300 in 'hotel' expenses, excluding management. As this excludes treatment costs, it is likely to underestimate the resource implications.</p> <p>A cost-minimisation analysis suggests that, ceteris paribus, and excluding pneumothorax, using Cortrak instead of blind NET placement could save the NHS money while almost eliminating the risk of never events, pneumothorax and, presumably, other</p> | | |

| Stakeholder | Do you agree that the guidance should not be updated? | Comments on equality issues or areas excluded from the original scope | Comments If you disagree please explain why | Response |
|-------------|---|---|--|----------|
| | | <p>complications associated with NET misplacement. In addition, cost savings using conservative assumptions on a few domains seem to offset Cortrak's acquisition price. While the assumptions are subject to uncertainty, the size of the difference and the consistency with a variety of studies from diverse settings (all of which report Cortrak is cost-effective), suggests that our conclusions are robust. A cost-consequence analysis is underway for a planned MTEP submission.</p> <p>Because of the uncertainties surrounding many assumptions, our results are preliminary and will be revised for any formal submission for the CG32 review and the MTEP. On the other hand, the current estimate does not include costs and consequences associated with: treating cancers caused by x-rays; delayed nutritional support, hydration and medication; adverse events other than pneumothorax; reducing inappropriate total parental nutrition starts; and other lost opportunity costs for patient contract. (For instance, HCPs accompany some patients for x-rays.) Therefore, our preliminary figures are likely to underestimate the costs. While formal cost-consequence analyses need to quantify economic outcomes, the differences seem sufficiently large to indicate that Cortrak offers improved safety and efficiently without</p> | | |

| Stakeholder | Do you agree that the guidance should not be updated? | Comments on equality issues or areas excluded from the original scope | Comments If you disagree please explain why | Response |
|-------------|---|---|--|----------|
| | | <p>incurring additional costs and, probably, reducing pressure on resources.</p> <p>This combination of clinical efficacy, improved safety and reduced costs justifies, we believe, review and revision of section 1.7. Inclusion of Cortrak offers the opportunity to reduce the risk to patients, help control costs, improve effectiveness and minimise 'postcode' differences in outcomes and patient risk.</p> | | |

Appendix 2 - Decision matrix

Surveillance and identification of triggers for updating CG32. The table below provides summaries of the evidence/intelligence that were identified.

| Conclusions from previous surveillance reviews | Is there any new evidence/intelligence identified during this 8-year Evidence Update (2013) and surveillance review (2013/2014) that may change this conclusion? | Clinical feedback from the GDG | Conclusion of this 8-year surveillance review (2013/2014) |
|--|--|--|--|
| Organisation of nutrition support in hospital and the community | | | |
| <p><u>2-year review (2008)</u> Update not required after review of evidence</p> <p><u>5-year review (2011)</u> Five studies relating to nutrition support teams were identified.</p> <p>Two studies identified were related to nutrition support^{1,2}. One study compared individualised nutrition to routine care in patients who had had stroke and found increased quality of life and better maintenance of weight in the intervention group, but no difference in length of hospital stay.¹ The other study assessed the timing of nutritional support in patients undergoing treatment for cancer; it was found that individuals undergoing nutritional support before treatment had worse outcomes overall.² These</p> | <p>No.</p> <p><u>8-year Evidence Update (2013)</u> Five studies⁶⁻¹⁰ relating to continuity of nutrition support between the hospital and the community were identified. The Evidence Update concluded that the findings were consistent with the need to coordinate care between hospital and community as recommended by NICE CG32 and reiterated in NICE QS24, and there would therefore be no potential impact of evidence on current guideline recommendations.</p> <p><u>8-year surveillance review (2013/2014)</u> No. Three studies¹¹⁻¹³ on organisation of nutrition support in the hospital and the community were identified; findings of studies were in line with guideline recommendations.</p> | <p>One GDG member commented that there are inequalities in the provision of nutrition support in non-hospital settings and that these are not well addressed in the current guideline.</p> | <p>No new evidence was found that would warrant a change in current guideline recommendations.</p> <p>Feedback from the GDG is unlikely to impact on the guideline recommendations at this time.</p> |

| Conclusions from previous surveillance reviews | Is there any new evidence/intelligence identified during this 8-year Evidence Update (2013) and surveillance review (2013/2014) that may change this conclusion? | Clinical feedback from the GDG | Conclusion of this 8-year surveillance review (2013/2014) |
|---|--|---|--|
| <p>studies support current recommendations on general standards of nutritional care.</p> <p>Three studies analysed nutritional counselling vs standard care and found that energy intake, protein intake and quality of life were generally improved in the groups that received nutritional counselling.³⁻⁵ One study also reported decreased mortality in the group receiving nutritional counselling.³</p> | | | |
| Screening for malnutrition and the risk of malnutrition in hospital and the community | | | |
| <p><u>2-year review (2008)</u> Update not required after review of evidence</p> <p><u>5-year review (2011)</u> No studies relevant to the clinical area were identified</p> | <p>No.</p> <p><u>8-year Evidence Update (2013)</u> One study on malnutrition screening in hospital admissions among older people was identified;¹⁴ the study findings buttress the recommendation in the guideline to screen all patients admitted to hospital for malnutrition.</p> <p><u>8-year surveillance review (2013/2014)</u> Eight studies on screening for malnutrition and the risk of malnutrition in hospital and the community were</p> | <p>No clinical feedback was provided for this section of the guideline.</p> | <p>New evidence is consistent with guideline recommendations</p> |

| Conclusions from previous surveillance reviews | Is there any new evidence/intelligence identified during this 8-year Evidence Update (2013) and surveillance review (2013/2014) that may change this conclusion? | Clinical feedback from the GDG | Conclusion of this 8-year surveillance review (2013/2014) |
|--|---|--|---|
| | identified; ¹⁵⁻²² findings of studies were broadly in line with guideline recommendations | | |
| Indications for nutrition support in hospital and the community | | | |
| <u>2-year review (2008)</u> Update not required after review of evidence <u>5-year review (2011)</u> No studies relevant to the clinical area were identified | <u>8-year Evidence Update (2013)</u> No studies relevant to the clinical area were identified <u>8-year surveillance review (2013/2014)</u> No studies relevant to the clinical area were identified | No clinical feedback was provided for this section of the guideline. | No relevant evidence identified |
| What to give in hospital and the community | | | |
| <u>2-year review (2008)</u> Update not required after review of evidence <u>5-year review (2011)</u> No studies relevant to the clinical area were identified | No. <u>8-year Evidence Update (2013)</u> Two observational UK studies ^{23,24} on the incidence of and risk factors for refeeding syndrome were identified. In both studies, the risk of refeeding syndrome was determined using the criteria set out in this guideline. One study ²³ concluded that starvation and baseline low-serum magnesium concentration were independent predictors for refeeding syndrome. | One GDG member highlighted that there has been considerable debate about the safety of the refeeding recommendations in the guideline and that this needs to be revisited and rewritten to prevent overly cautious approaches to feeding which in itself can hold risks. | No new evidence was found that would change the direction of current guideline recommendations; feedback from the GDG is also unlikely to impact on the guideline recommendations at this time. |

| Conclusions from previous surveillance reviews | Is there any new evidence/intelligence identified during this 8-year Evidence Update (2013) and surveillance review (2013/2014) that may change this conclusion? | Clinical feedback from the GDG | Conclusion of this 8-year surveillance review (2013/2014) |
|---|---|-----------------------------------|---|
| | <p>The other study²⁴, using hypophosphataemia as the 'reference standard', found that the NICE criteria for defining risk of refeeding syndrome had a sensitivity and specificity of 0.76 and 0.50 respectively for nasogastric feeding, and 0.73 and 0.38 respectively for parenteral feeding.</p> <p>The Evidence Update concluded that taken together, the evidence is broadly consistent with the guideline, and although the findings of the studies question the validity or lack of specificity of some risk markers set out by NICE, the lack of universally accepted criteria for a diagnosis of refeeding syndrome prevents a definitive assessment. Hence this evidence is unlikely to have an impact on NICE CG32; further research is therefore needed.</p> <p><u>8-year surveillance review (2013/2014)</u></p> <p>No studies relevant to the clinical area were identified.</p> | | |
| Monitoring of nutrition support in hospital and the community | | | |
| <u>2-year review (2008)</u> | No. | No clinical feedback was provided | No relevant evidence identified |

| Conclusions from previous surveillance reviews | Is there any new evidence/intelligence identified during this 8-year Evidence Update (2013) and surveillance review (2013/2014) that may change this conclusion? | Clinical feedback from the GDG | Conclusion of this 8-year surveillance review (2013/2014) |
|--|--|---|---|
| <p>Update not required after review of evidence</p> <p><u>5-year review (2011)</u></p> <p>No studies relevant to the clinical area were identified</p> | <p><u>8-year Evidence Update (2013)</u></p> <p>No studies relevant to the clinical area were identified</p> <p><u>8-year surveillance review (2013/2014)</u></p> <p>No studies relevant to the clinical area were identified</p> | <p>for this section of the guideline.</p> | |
| <p>Oral nutrition support in hospital and the community</p> | | | |
| <p><u>2-year review (2008)</u></p> <p>Update not required after review of evidence</p> <p><u>5-year review (2011)</u></p> <p>Thirteen studies²⁵⁻³⁷ relevant to the clinical area were identified.</p> <p>Several studies, comparing oral nutritional supplements with either standard care or dietary counselling generally showed that giving oral nutritional supplements improves various outcomes such as weight gain, quality of life and decreased postoperative complications^{25-28,30,33,35-37}. One of these studies includes a trial based economic evaluation³⁵. These</p> | <p>No.</p> <p><u>8-year Evidence Update (2013)</u></p> <p>Eight studies³⁸⁻⁴⁵ relating to oral nutrition support in hospital and the community were identified.</p> <p>The key point from one of the studies⁴⁵ was that immune enhancing nutrition (which were outside the scope of CG32) may reduce postoperative complications in patients undergoing non-emergency gastrointestinal surgery. However, the Evidence Update contended that limitations of the evidence, combined with some potential issues of adverse reactions to immune enhancing supplements in critical care populations noted by the authors of the Cochrane</p> | <p>One GDG member commented that that new recommendations on the use of oral nutrition supplements in the community where practice is highly variable could be made</p> | <p>No new evidence was identified which would change the direction of current guideline recommendations.</p> <p>Feedback from the GDG is unlikely to impact on the guideline recommendations at this time.</p> <p>Further evidence relating to immune enhancing nutrition, identified in the Evidence Update in the study by Burden et al. 2012⁴⁵ is discussed below under the heading: Area not currently covered in the guideline - Immunonutrition]</p> |

| Conclusions from previous surveillance reviews | Is there any new evidence/intelligence identified during this 8-year Evidence Update (2013) and surveillance review (2013/2014) that may change this conclusion? | Clinical feedback from the GDG | Conclusion of this 8-year surveillance review (2013/2014) |
|--|--|---|---|
| <p>studies strengthen the recommendation for oral nutritional supplementation with various care settings, especially within the community.</p> <p>One study looked at oral nutritional supplements (ONS) vs standard care and identified that for ONS to be effective, more than one meal should be enhanced²⁹</p> <p>One study found that early oral nutrition compared to traditional oral feeding resulted in a shorter length of hospital stay³¹, however the evidence was not deemed sufficient to merit a change in the guidance.</p> <p>One study was identified that provided evidence for nutritional care in dementia³²</p> | <p>review, mean that this finding is unlikely to affect CG32. However, further research into the effects of perioperative nutrition support across the spectrum of nutritional status, not just malnourished patients, may be useful.</p> <p><u>8-year surveillance review (2013/2014)</u></p> <p>Twelve studies^{40,46-57} on oral nutrition support in hospital and the community were identified; findings of studies were broadly consistent with guideline recommendations.</p> | | |
| Enteral tube feeding in hospital and the community | | | |
| <p><u>2-year review (2008)</u></p> <p>Update not required after review of evidence</p> <p><u>5-year review (2011)</u></p> | <p>No.</p> <p><u>8-year Evidence Update (2013)</u></p> <p>Five studies⁷⁰⁻⁷⁴ relating to enteral tube feeding in hospital and the community were identified.</p> | <p>One GDG member pointed out that there has been further NPSA guidance around nasogastric feeding tube safety.</p> | <p>No new evidence was identified which would change the direction of current guideline recommendations.</p> <p>The point around safety of nasogastric tube feeding raised by a</p> |

| Conclusions from previous surveillance reviews | Is there any new evidence/intelligence identified during this 8-year Evidence Update (2013) and surveillance review (2013/2014) that may change this conclusion? | Clinical feedback from the GDG | Conclusion of this 8-year surveillance review (2013/2014) |
|--|---|--------------------------------|--|
| <p>Twelve studies⁵⁸⁻⁶⁹ relevant to the clinical area were identified.</p> <p>One study addressed immediate optimum flow rate vs incremental optimum flow rate for enteral feeding, and found that the immediate flow-rate group had significantly more calories and higher residual gastric volumes than the incremental flow rate⁵⁸</p> <p>Three studies were identified that are of note for nutrition in intensive care units. One study looked at the timing of enteral nutrition (early vs late enteral nutrition) and found that delayed feeding resulted in a longer stay in ICU⁶⁶, another study found that early enteral feeding after Gastrointestinal surgery resulted in higher transferring levels and a quicker return of bowel sounds, but resulted in more episodes of diarrhoea and stomach cramps⁶⁸.</p> <p>One study assessed the effect of tube placement on ICU patients (post pyloric vs nasogastric)⁶⁷ and found that there was no difference between groups with respect to length of</p> | <p>The key point from one of the studies⁷⁴ was that acupuncture may have benefits over standard motility drugs in treating delayed gastric emptying in critical care. However, this was a very small (30 participants), single-blinded trial, and the Evidence Update contended that limitations of the evidence mean that it is unlikely to have an impact on CG32 and further research is needed.</p> <p><u>8-year surveillance review (2013/2014)</u></p> <p>Three studies⁷⁵⁻⁷⁷ on enteral tube feeding were identified; findings of studies were broadly consistent with guideline recommendations.</p> | | <p>GDG member was also raised at the last review in 2011; it was addressed as follows: "One GDG member was concerned about the harm caused by misplaced nasogastric feeding tubes in adults, which has also been a subject of a recent NPSA safety warning. The main causal factor leading to harm was misinterpretation of x-rays, therefore the safety alert incorporated specific steps for healthcare professionals to follow during nasogastric tube insertion. However, no evidence was found during the high level RCT search and no other member raised this issue".</p> |

| Conclusions from previous surveillance reviews | Is there any new evidence/intelligence identified during this 8-year Evidence Update (2013) and surveillance review (2013/2014) that may change this conclusion? | Clinical feedback from the GDG | Conclusion of this 8-year surveillance review (2013/2014) |
|--|--|--------------------------------|---|
| <p>hospital stay and number of ventilator days, but the nasogastric group had better outcomes with regards to nutritional status (increased calorie intake and reached target feed in a shorter time).</p> <p>A UK cost utility analysis⁶⁹ was identified that looked at the setting of enteral nutrition in patients with cerebrovascular accident, and found in favour of enteral nutrition being undertaken in the home rather than in nursing homes. This evidence is not sufficient to alter the current guideline.</p> <p>Five studies were identified that may affect guidance with regards to enteral vs parenteral nutrition in various clinical settings including patients who had undergone GI surgery and patients with severe acute pancreatitis^{59,61-64}; one found that enteral nutrition resulted in a bigger decline in quality of life than parenteral nutrition, yet parenteral nutrition resulted in more complications⁶¹, another study found greater patient satisfaction with enteral nutrition⁶² and</p> | | | |

| Conclusions from previous surveillance reviews | Is there any new evidence/intelligence identified during this 8-year Evidence Update (2013) and surveillance review (2013/2014) that may change this conclusion? | Clinical feedback from the GDG | Conclusion of this 8-year surveillance review (2013/2014) |
|---|--|--------------------------------|---|
| <p>another study found decreased mortality in enteral nutrition.⁶⁴ One study found that motilin and cholecystokinin were increased in the enteral nutrition group, and that they had improve electrogastrography post-operatively.⁶³</p> <p>One study looked at enteral nutrition vs parenteral+enteral nutrition in patients undergoing pancreoduodectomy and found that there was no difference between groups with regards to mortality, but enteral group had a higher discontinuation of feeding, and the enteral+parenteral group had a longer duration of feed and had their line maintained for longer.⁶⁵</p> <p>One study looked at early enteral nutrition vs early natural nutrition⁶⁰ in pancreoduodectomy patients, and found that early enteral nutrition received more energy in the first 5 days post-operatively than the early natural nutrition group, there were also more complications in the early natural nutrition group</p> | | | |

| Conclusions from previous surveillance reviews | Is there any new evidence/intelligence identified during this 8-year Evidence Update (2013) and surveillance review (2013/2014) that may change this conclusion? | Clinical feedback from the GDG | Conclusion of this 8-year surveillance review (2013/2014) |
|--|--|---|--|
| Parenteral nutrition in hospital and the community | | | |
| <p><u>2-year review (2008)</u> Update not required after review of evidence</p> <p><u>5-year review (2011)</u> Five studies^{62,78-81} relevant to the clinical area were identified.</p> <p>One study in trauma patients looked at partial parenteral vs enteral nutrition and found that the parenteral nutrition group received more protein and calories and had higher albumin and transferrin concentrations^{78,80,81}</p> <p>There are two trial based economic evaluations^{62,79} which favoured enteral over parenteral nutrition in terms of cost, without finding differences in clinical outcomes. This evidence supports the existing recommendation.</p> | <p>No.</p> <p><u>8-year Evidence Update (2013)</u> No studies relevant to the clinical area were identified</p> <p><u>8-year surveillance review (2013/2014)</u> Two studies^{82,83} on parenteral nutrition were identified. The study by Casaer et al. 2011⁸² is the report of the EPaNIC trial that was identified at the 5-year review in 2011. The study compared early (within 24-48 hours, European guideline) versus late (after 7 days, American/Canadian guideline) initiation of PN when EN fails to reach a caloric target and concluded that late initiation of parenteral nutrition was associated with faster recovery and fewer complications, as compared with early initiation.</p> <p>The other study⁸³ aimed to assess outcomes of parenteral nutrition when the NICE guidance was adhered to. It concluded that implementing the guidelines may not be enough to reduce</p> | <p>No clinical feedback was provided for this section of the guideline.</p> | <p>The identified new evidence would not change the direction of current guideline recommendations. It would be appropriate to await the results of a large ongoing UK multi-centre study (the CALORIE trial) that is due for completion in December 2015.</p> |

| Conclusions from previous surveillance reviews | Is there any new evidence/intelligence identified during this 8-year Evidence Update (2013) and surveillance review (2013/2014) that may change this conclusion? | Clinical feedback from the GDG | Conclusion of this 8-year surveillance review (2013/2014) |
|---|--|---|---|
| | <p>mortality and other outcomes. The authors also posited that in view of the fact that the guideline recommendations were mostly based on Grade D evidence due to absence of randomised controlled trials, new interventions or changes in clinical practice should be considered to optimise the impact of parenteral nutrition on mortality.</p> <p>However, there is a large ongoing multicentre UK RCT (the NIHR HTA-sponsored CALORIE trial) that is expected to report in December 2015, and it would be appropriate to wait for the publication of the results of the trial to look at this again.</p> | | |
| Supporting patients in the community | | | |
| <p><u>2-year review (2008)</u> Update not required after review of evidence</p> <p><u>5-year review (2011)</u> No studies relevant to the clinical area were identified</p> | <p>No.</p> <p><u>8-year Evidence Update (2013)</u> No studies relevant to the clinical area were identified</p> <p><u>8-year surveillance review (2013/2014)</u> No studies relevant to the clinical area were identified</p> | <p>No clinical feedback was provided for this section of the guideline.</p> | <p>No relevant evidence identified</p> |

| Conclusions from previous surveillance reviews | Is there any new evidence/intelligence identified during this 8-year Evidence Update (2013) and surveillance review (2013/2014) that may change this conclusion? | Clinical feedback from the GDG | Conclusion of this 8-year surveillance review (2013/2014) |
|--|--|--|--|
| Area not currently covered in the guideline - Nutrition support in stroke, liver disease | | | |
| <p><u>5-year review (2011)</u></p> <p>Nutrition in people requiring specific long-term therapeutic regimens for the treatment of diseases was excluded from the original scope. Thus no study was identified from the high level searches on this area. However, during consultation, one stakeholder suggested that this was an important area that warranted inclusion in the guideline and provided information on publications relating to nutrition in chronic liver disease.</p> | <p>No.</p> <p><u>8-year Evidence Update (2013)</u></p> <p>Two Cochrane reviews, one each on a range of interventions for nutrition support in people with stroke⁸⁴ and liver disease⁸⁵ were identified - these two studies examined a wider range of interventions within specific conditions, and were therefore deemed not to be aligned to any particular section of the guideline.</p> <p>Alongside general recommendations for nutrition support in CG32, guidance specific to nutrition support in stroke is covered by the NICE 'Stroke' guideline CG68. On the basis of the findings of the Cochrane review on nutrition interventions in stroke⁸⁴, the Evidence Update concluded that the evidence is unlikely to have an impact on the stroke guideline recommendations and the evidence for reduced pressure sores is broadly consistent with recommendations for general nutrition support in CG32.</p> | <p>No clinical feedback was provided on this topic</p> | <p>Alongside general recommendations for nutrition support in CG32, guidance specific to nutrition support in stroke is covered by the NICE 'Stroke' guideline CG68; the identified new evidence is unlikely to have an impact on the stroke guideline recommendations and is broadly consistent with recommendations for general nutrition support in CG32.</p> <p>The identified new evidence on nutrition support in liver disease is insufficient to warrant an update of the guideline.</p> |

| Conclusions from previous surveillance reviews | Is there any new evidence/intelligence identified during this 8-year Evidence Update (2013) and surveillance review (2013/2014) that may change this conclusion? | Clinical feedback from the GDG | Conclusion of this 8-year surveillance review (2013/2014) |
|--|---|--------------------------------|---|
| | <p>The results of the Cochrane review on nutritional support for liver disease⁸⁵ revealed no significant differences for most analyses and the Evidence Update concluded that although the evidence suggests that the benefits of nutrition support in patients with liver disease appear to be restricted, limitations of current data prevent firm conclusions and more robust evidence is needed to confirm findings.</p> <p><u>8-year surveillance review (2013/2014)</u></p> <p>One systematic review and meta-analysis⁸⁶ of RCTs of oral or enteral nutritional supplementation in adult patients with cirrhosis was found. Results showed that there was no reduction in mortality when all studies were combined. The authors concluded that there is insufficient evidence to definitively state that the intervention impacts clinical outcomes in liver cirrhosis.</p> | | |

| Conclusions from previous surveillance reviews | Is there any new evidence/intelligence identified during this 8-year Evidence Update (2013) and surveillance review (2013/2014) that may change this conclusion? | Clinical feedback from the GDG | Conclusion of this 8-year surveillance review (2013/2014) |
|--|--|--|---|
| Area not currently covered in the guideline – Immunonutrition (including the use of novel substrates such as glutamine or arginine) | | | |
| <p><u>5-year review (2011)</u></p> <p>Although the use of novel substrates such as glutamine or arginine was excluded from the scope of the guideline, at the 5-year review, immunonutrition was considered an emerging topic that might warrant inclusion in the scope of a future update of the guideline. A focused search on immunonutrition was therefore undertaken and 35 studies⁸⁷⁻¹²¹ were identified for inclusion in the review.</p> <p>Six studies were related to the area of parenteral immunonutrition in a varied patient population (GI cancer, severe acute pancreatitis and critically ill patients): Three studies analysed the effect of varying quantities of omega 3 and fish oils in TPN⁸⁷⁻⁸⁹, two studies addressed the effect of varying lipid composition of TPN^{91,92}, and one study looked at the effects of varying the amino acid content of TPN⁹³. The largest study (166 patients in an intensive care setting) found no</p> | <p>No.</p> <p><u>8-year Evidence Update (2013)</u></p> <p>The key point from one of the Cochrane reviews⁴⁵ included in the oral nutrition section of the Evidence Update was that immune enhancing nutrition may reduce postoperative complications in patients undergoing non-emergency gastrointestinal surgery.</p> <p>However, the Evidence Update contended that limitations of the evidence, combined with some potential issues of adverse reactions to immune enhancing supplements in critical care populations noted by the authors of the review, mean that this finding is unlikely to affect CG32, and that further research into the effects of perioperative nutrition support across the spectrum of nutritional status, not just malnourished patients, may be useful.</p> <p><u>8-year surveillance review (2013/2014)</u></p> <p>Nine studies¹²⁵⁻¹³³ were identified through a high level search.</p> | <p>One GDG member commented that the field of immunonutrition was not included in the original guidance but since then a lot of research has been published which has led to massive variation in practice related to the prescription or otherwise of these more expensive nutritional support interventions.</p> | <p>The evidence relating to immunonutrition is promising - benefits were found in subgroups of high-risk and malnourished patients. However, conflicting results on the benefit of immunonutrition from several studies do not allow for any firm conclusions.</p> <p>The current evidence is therefore insufficient to merit inclusion of immunonutrition into the guideline at this stage</p> |

| Conclusions from previous surveillance reviews | Is there any new evidence/intelligence identified during this 8-year Evidence Update (2013) and surveillance review (2013/2014) that may change this conclusion? | Clinical feedback from the GDG | Conclusion of this 8-year surveillance review (2013/2014) |
|---|--|--------------------------------|---|
| <p>difference between groups with respect to inflammatory markers⁸⁷. Other, smaller studies found that the intervention reduced the concentration of inflammatory markers⁸⁹, and had beneficial effects on serum lipid profiles⁹² and reduced postoperative morbidity⁹³. Two studies could potentially inform health economic considerations of this new topic once conclusive clinical evidence is available^{90,122}.</p> <p>Ten studies were found that specifically looked at parenteral nutrition with glutamine vs standard parenteral nutrition^{111,113-121}. These studies were relatively small (all less than 75 patients) and undertaken on a variety of patient populations, including surgical and trauma patients and patients undergoing stem cell transplantation. Studies involving patients undergoing stem cell transplants found a higher C- reactive protein¹¹¹ and increased survival¹¹⁴ in the intervention group.</p> <p>One study assessing immunonutrition</p> | <p>One systematic review and meta-analysis¹²⁵ of RCTs published between 1985 and 2009 that assessed the clinical impact of perioperative enteral immunonutrition in major gastrointestinal elective surgery was found. The authors concluded that perioperative enteral immunonutrition decreases morbidity and hospital stay but not mortality after major gastrointestinal surgery.</p> <p>One large RCT¹²⁶ conducted in Scotland showed no effect on new infections or on mortality when parenteral nutrition was supplemented with glutamine or selenium.</p> <p>One large multi-centre RCT¹²⁷ conducted in Europe and North America concluded that early provision of glutamine or antioxidants did not improve clinical outcomes, and that glutamine was associated with an increase in mortality among critically ill patients with multiorgan failure.</p> <p>Preliminary data from one small French RCT¹²⁸ showed that immunonutrition improves functional capacities in head, neck and oesophageal cancer patients</p> | | |

| Conclusions from previous surveillance reviews | Is there any new evidence/intelligence identified during this 8-year Evidence Update (2013) and surveillance review (2013/2014) that may change this conclusion? | Clinical feedback from the GDG | Conclusion of this 8-year surveillance review (2013/2014) |
|---|--|--------------------------------|---|
| <p>in chronic obstructive pulmonary disease found the intervention group had a significantly higher CD3 concentration and a decreased TNFα¹¹⁹. One study assessing immunonutrition in gastrointestinal surgery found that there was not a significant difference between the control and intervention groups - both groups showed decreases in albumin, CRP, lymphocyte count, T cell and CD8 count after surgery¹²¹. Studies also showed improved survival¹¹⁴, incidence of specific infections¹¹⁵, and decreased intolerance to feeding¹²³.</p> <p>Eleven studies pertaining to the area of enteral immunonutrition were identified. Studies involved looking at immunonutrition vs standard enteral nutrition^{94,94,94,96-103,112,124}. One study looked at immunoenhanced enteral nutrition vs standard parenteral nutrition. Immunonutrition refers to the addition of substances such as arginine, eicosapentonic acid (EPA) and gammalinoleic acid (GLA) to the nutrition. In the majority of studies patients receiving immunonutrition</p> | <p>undergoing radiochemotherapy.</p> <p>One small RCT¹²⁹ conducted in China concluded that arginine-supplemented enteral nutrition significantly improves long-term survival and restores immunity in malnourished gastric cancer patients.</p> <p>A systematic review and meta-analysis¹³⁰ of RCTs found that fish oil-containing lipid emulsions may be able to decrease mortality and ventilation days in the critically ill. However, the authors concluded that because of the paucity of clinical data, there is inadequate evidence to recommend the routine use of parenteral fish oil and that large, rigorously designed RCTs are required to elucidate the efficacy of parenteral fish oil in the critically ill.</p> <p>Another systematic review and meta-analysis¹³¹ concluded that omega-3 fatty acid supplementation of parenteral nutrition does not improve mortality, infectious complications, and intensive therapy unit length of stay in comparison with standard parenteral nutrition in critically ill adult patients.</p> | | |

| Conclusions from previous surveillance reviews | Is there any new evidence/intelligence identified during this 8-year Evidence Update (2013) and surveillance review (2013/2014) that may change this conclusion? | Clinical feedback from the GDG | Conclusion of this 8-year surveillance review (2013/2014) |
|---|---|--------------------------------|---|
| <p>tend to have better outcomes with regards to inflammatory markers, mortality, ventilator and ICU free days^{59,94-101,102,103,112}.</p> <p>There were seven studies pertaining to the area of oral immunonutrition^{107,124,105-110,124}. These included studies comparing oral nutritional supplements with substances such as arginine, zinc, testosterone, polyunsaturated omega-3 and oligosaccharides with standard oral nutrition. The majority of studies looked at an elderly population in the community or nursing home facilities^{108,109,124}, one study looked at stroke patients¹⁰⁶, and one looked at patients with gastrointestinal tumours¹⁰⁷. Some studies showed a trend towards decrease in hospital admissions, decreased length of stay, and decreased mortality^{105,106,124}. One study specifically looked at antibody titres with respect to a population at risk from influenza; the usefulness of this study is restricted as it addresses a very specific and indirect population¹⁰⁸. Two studies looked at biochemical</p> | <p>One small RCT¹³² conducted in Brazil found that fish oil decreases c-reactive protein/albumin ratio and plasma fatty acid profile and potentially prevents weight loss in people with colorectal cancer.</p> <p>One small RCT¹³³ conducted in Taiwan found that Omega-3 fatty acid-, micronutrient-, and probiotic-enriched nutrition helps body weight stabilization in head and neck cancer cachexia.</p> <p>Put together, the evidence relating to immunonutrition is promising - benefits were found in subgroups of high-risk and malnourished patients. However, conflicting results of effectiveness of immunonutrition products from several studies and even of harm in at least one study¹²⁷, do not allow for a firm conclusion.</p> | | |

| Conclusions from previous surveillance reviews | Is there any new evidence/intelligence identified during this 8-year Evidence Update (2013) and surveillance review (2013/2014) that may change this conclusion? | Clinical feedback from the GDG | Conclusion of this 8-year surveillance review (2013/2014) |
|--|--|--------------------------------|---|
| <p>indices, one study found a beneficial reduction in TNFα mRNA and IL6 mRNA in the intervention group,¹⁰⁹ and another study found that biochemical markers indicated a decrease in immune suppression in patients receiving immunonutrition intervention.¹¹⁰ All of the studies listed here are of limited relevance as they were all carried out on relatively small populations (all less than 100 patients) and the results are inconclusive.</p> <p>The 5-year review concluded that no sufficient conclusive evidence was identified that would merit inclusion of immunonutrition into the guideline at that stage.</p> | | | |

References

1. Ha L, Hauge T, Spenning AB et al. (2010) Individual, nutritional support prevents undernutrition, increases muscle strength and improves QoL among elderly at nutritional risk hospitalized for acute stroke: a randomized, controlled trial. *Clinical Nutrition* 29:567-573.
2. Rabinovitch R. (2006) Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03. *Head & Neck* 28:287-296.
3. Duncan DG, Beck SJ, Hood K et al. (2006) Using dietetic assistants to improve the outcome of hip fracture: A randomised controlled trial of nutritional support in an acute trauma ward. *Age and Ageing* 35:148-153.
4. Fenacht U, hlin M, Wegmann M et al. (2010) Nutritional counseling improves quality of life and nutrient intake in hospitalized undernourished patients. *Nutrition* 26:53-60.
5. Isenring EA BJC. (2007) Nutrition support using the American Dietetic Association medical nutrition therapy protocol for radiation oncology patients improves dietary intake compared with standard practice. *Journal of the American Dietetic Association* 107:404-412.
6. Feldblum I, German L, Castel H et al. (2011) Individualized nutritional intervention during and after hospitalization: the nutrition intervention study clinical trial. *Journal of the American Geriatrics Society* 59:10-17.
7. Neelemaat F, Bosmans JE, Thijs A et al. (2011) Post-discharge nutritional support in malnourished elderly individuals improves functional limitations. *Journal of the American Medical Directors Association* 12:295-301.
8. Neelemaat F, Bosmans JE, Thijs A et al. (2012) Oral nutritional support in malnourished elderly decreases functional limitations with no extra costs. *Clinical Nutrition* 31:183-190.
9. Beck AM, Holst M, and Rasmussen HH. (2013) Oral nutritional support of older (65 years+) medical and surgical patients after discharge from hospital: systematic review and meta-analysis of randomized controlled trials. *Clinical Rehabilitation* 27:19-27.
10. Norman K, Pirlich M, Smoliner C et al. (2011) Cost-effectiveness of a 3-month intervention with oral nutritional supplements in disease-related malnutrition: a randomised controlled pilot study. *European Journal of Clinical Nutrition* 65:735-742.
11. Young AM, Mudge AM, Banks MD et al. (2013) Encouraging, assisting and time to EAT: Improved nutritional intake for older medical patients receiving Protected Mealtimes and/or additional nursing feeding assistance. *Clinical Nutrition* 32:543-549.
12. Perry L, Hamilton S, Williams J et al. (2013) Nursing interventions for improving nutritional status and outcomes of stroke patients: descriptive reviews of processes and outcomes. *Worldviews on evidence-based nursing / Sigma Theta Tau International, Honor Society of Nursing* 10:17-40.
13. Kim H, Suh EE, Lee HJ et al. (29-4-2013) The Effects of Patient Participation-Based Dietary Intervention on Nutritional and Functional Status for Patients With Gastrectomy: A Randomized Controlled Trial. *Cancer Nurs* .
14. Holyday M, Daniells S, Bare M et al. (2012) Malnutrition screening and early nutrition intervention in hospitalised patients in acute aged care: a randomised controlled trial. *Journal of Nutrition, Health & Aging* 16:562-568.
15. Carey S, Ferrie S, Ryan R et al. (2013) Long-term nutrition intervention following major upper gastrointestinal surgery: A prospective randomized controlled trial. *European Journal of Clinical Nutrition* 67:324-329.

16. Green SM and James EP. (2013) Barriers and facilitators to undertaking nutritional screening of patients: a systematic review. *J Hum.Nutr Diet* 26:211-221.
17. Nykanen I, Lonroos E, Kautiainen H et al. (2013) Nutritional screening in a population-based cohort of community-dwelling older people. *Eur.J Public Health* 23:405-409.
18. Omidvari AH, Vali Y, Murray SM et al. (2013) Nutritional screening for improving professional practice for patient outcomes in hospital and primary care settings. *Cochrane database of systematic reviews (Online)* 6:CD005539.
19. Roque M, Salva A, and Vellas B. (2013) Malnutrition in community-dwelling adults with dementia (Nutrialz Trial). *Journal of Nutrition, Health and Aging* 17:295-299.
20. Tamura BK, Bell CL, Masaki KH et al. (2013) Factors Associated With Weight Loss, Low BMI, and Malnutrition Among Nursing Home Patients: A Systematic Review of the Literature. *J AM MED DIR ASSOC* 14:649-655.
21. Vashi PG, Gupta D, Lammersfeld CA et al. (2013) The relationship between baseline nutritional status with subsequent parenteral nutrition and clinical outcomes in cancer patients undergoing hyperthermic intraperitoneal chemotherapy. *Nutrition Journal* 12.
22. Li HJ, Cheng HS, Liang J et al. (2013) Functional recovery of older people with hip fracture: does malnutrition make a difference? *J Adv.Nurs* 69:1691-1703.
23. Rio A, Whelan K, Goff L et al. (2013) Occurrence of refeeding syndrome in adults started on artificial nutrition support: prospective cohort study. *BMJ Open* 3.
24. Zeki S, Culkin A, Gabe SM et al. (2011) Refeeding hypophosphataemia is more common in enteral than parenteral feeding in adult in patients. *Clinical nutrition (Edinburgh, Scotland)* 30:365-368.
25. Beck AM DK. (2008) Multifaceted nutritional intervention among nursing-home residents has a positive influence on nutrition and function. *Nutrition (Burbank, Los Angeles County, Calif)* 24:1073-1080.
26. Beck AM, Damkjaer K, and rbye LW. (2010) Physical and social functional abilities seem to be maintained by a multifaceted randomized controlled nutritional intervention among old (>65 years) Danish nursing home residents. *Archives of Gerontology & Geriatrics* 50:351-355.
27. Botella-Carretero JI, Iglesias B, Balsa JA et al. (2008) Effects of oral nutritional supplements in normally nourished or mildly undernourished geriatric patients after surgery for hip fracture: a randomized clinical trial. *Jpen: Journal of Parenteral & Enteral Nutrition* 32:120-128.
28. Botella-Carretero JI, Iglesias B, Balsa JA et al. (2010) Perioperative oral nutritional supplements in normally or mildly undernourished geriatric patients submitted to surgery for hip fracture: a randomized clinical trial. *Clinical Nutrition* 29:574-579.
29. Castellanos VH, Marra MV, and Johnson P. (2009) Enhancement of Select Foods at Breakfast and Lunch Increases Energy Intakes of Nursing Home Residents with Low Meal Intakes. *Journal of the American Dietetic Association* 109:445-451.
30. McMurdo ME, Price RJ, Shields M et al. (2009) Should oral nutritional supplementation be given to undernourished older people upon hospital discharge? A controlled trial. *Journal of the American Geriatrics Society* 57:2239-2245.
31. Minig L, Biffi R, Zanagnolo V et al. (2009) Early oral versus "traditional" postoperative feeding in gynecologic oncology patients undergoing intestinal resection: a randomized controlled trial. *Annals of Surgical Oncology* 16:1660-1668.

32. Navratilova M, Jarkovsky J, Ceskova E et al. (2007) Alzheimer disease: Malnutrition and nutritional support. *Clinical and Experimental Pharmacology and Physiology* 34:S11-S13.
33. Norman K, Kirchner H, Freudenreich M et al. (2008) Three month intervention with protein and energy rich supplements improve muscle function and quality of life in malnourished patients with non-neoplastic gastrointestinal disease--a randomized controlled trial. *Clinical Nutrition* 27:48-56.
34. Ravasco P. (2005) Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. *Head & Neck* 27:659-668.
35. Simmons SF ZX. (2010) Cost-effectiveness of nutrition interventions in nursing home residents: a pilot intervention. *The journal of nutrition, health & aging* 14:367-372.
36. van Anholt RD, Sobotka L, Meijer EP et al. (2010) Specific nutritional support accelerates pressure ulcer healing and reduces wound care intensity in non-malnourished patients. *Nutrition* 26:867-872.
37. Wouters-Wesseling W. (2006) Early nutritional supplementation immediately after diagnosis of infectious disease improves body weight in psychogeriatric nursing home residents. *Aging clinical and experimental research* 18:70-74.
38. Starke J, Schneider H, Alteheld B et al. (2011) Short-term individual nutritional care as part of routine clinical setting improves outcome and quality of life in malnourished medical patients. *Clinical Nutrition* 30:194-201.
39. Baldwin C and Weekes CE. (2011) Dietary advice with or without oral nutritional supplements for disease-related malnutrition in adults. *Cochrane Database of Systematic Reviews* CD002008.
40. Myint MW, Wu J, Wong E et al. (2013) Clinical benefits of oral nutritional supplementation for elderly hip fracture patients: a single blind randomised controlled trial. *Age & Ageing* 42:39-45.
41. Baldwin C, Spiro A, Ahern R et al. (7-3-2012) Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. *Journal of the National Cancer Institute* 104:371-385.
42. Collins PF, Stratton RJ, and Elia M. (2012) Nutritional support in chronic obstructive pulmonary disease: a systematic review and meta-analysis. *American Journal of Clinical Nutrition* 95:1385-1395.
43. Collins PF, Elia M, and Stratton RJ. (1-5-2013) Nutritional support and functional capacity in chronic obstructive pulmonary disease: A systematic review and meta-analysis. *Respirology* 18:616-629.
44. Ferreira IM, Brooks D, White J et al. (2012) Nutritional supplementation for stable chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* CD000998.
45. Burden S, Todd C, Hill J et al. (2012) Pre-operative Nutrition Support in Patients Undergoing Gastrointestinal Surgery. *Cochrane Database of Systematic Reviews* CD008879.
46. Gurgun A, Deniz S, Argin M et al. (2013) Effects of nutritional supplementation combined with conventional pulmonary rehabilitation in muscle-wasted chronic obstructive pulmonary disease: A prospective, randomized and controlled study. *Respirology* 18:495-500.
47. Karandish M, Tamimi M, Shayesteh AA et al. (2013) The effect of magnesium supplementation and weight loss on liver enzymes in patients with nonalcoholic fatty liver disease. *Journal of Research in Medical Sciences* 18:572-578.

48. Khoshbaten M, Ghaffarifar S, Jabbar Imani A et al. (2013) Effects of early oral feeding on relapse and symptoms of upper gastrointestinal bleeding in peptic ulcer disease. *Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society* 25:125-129.
49. Lee J and Finucane T. (2013) Thought for food: Is nutritional supplementation an effective treatment for malnutrition? *Journal of the American Geriatrics Society* 61:S161.
50. Lee LC, Tsai AC, Wang JY et al. (3-5-2013) Need-based intervention is an effective strategy for improving the nutritional status of older people living in a nursing home: A randomized controlled trial. *Int J Nurs Stud* .
51. Leslie WS, Woodward M, Lean ME et al. (2013) Improving the dietary intake of under nourished older people in residential care homes using an energy-enriching food approach: a cluster randomised controlled study. *J Hum.Nutr Diet* 26:387-394.
52. Locher JL, Vickers KS, Buys DR et al. (7-9-2013) A Randomized Controlled Trial of a Theoretically-Based Behavioral Nutrition Intervention for Community Elders: Lessons Learned from the Behavioral Nutrition Intervention for Community Elders Study. *Journal of the Academy of Nutrition and Dietetics* .
53. Marinari S, Manigrasso MR, and De BF. (2013) Effects of nutraceutical diet integration, with coenzyme Q10 (Q-Ter multicomposite) and creatine, on dyspnea, exercise tolerance, and quality of life in COPD patients with chronic respiratory failure. *Multidisciplinary Respiratory Medicine* 8.
54. Stratton RJ, Hebuterne X, and Elia M. (2013) A systematic review and meta-analysis of the impact of oral nutritional supplements on hospital readmissions. *Ageing Research Reviews* 12:884-897.
55. Wang Y, Liu XJ, Robitaille L et al. (2013) Effects of vitamin C and vitamin D administration on mood and distress in acutely hospitalized patients. *American Journal of Clinical Nutrition* 98:705-711.
56. Stange I, Bartram M, Liao Y et al. (2013) Effects of a low-volume, nutrient- and energy-dense oral nutritional supplement on nutritional and functional status: A randomized, controlled trial in nursing home residents. *Journal of the American Medical Directors Association* 14:628.
57. Bouillanne O, Curis E, Hamon-Vilcot B et al. (2013) Impact of protein pulse feeding on lean mass in malnourished and at-risk hospitalized elderly patients: a randomized controlled trial. *Clin Nutr* 32:186-192.
58. Desachy A. (2008) Initial efficacy and tolerability of early enteral nutrition with immediate or gradual introduction in intubated patients. *Intensive Care Medicine* 34:1054-1059.
59. Doley RP YTWJK. (2009) Enteral nutrition in severe acute pancreatitis. *JOP : Journal of the pancreas* 10:157-162.
60. Grizas S G. (2008) A comparison of the effectiveness of the early enteral and natural nutrition after pancreatoduodenectomy. *Medicina (Kaunas, Lithuania)* 44:678-686.
61. Hyltander A. (2005) Supportive nutrition on recovery of metabolism, nutritional state, health-related quality of life, and exercise capacity after major surgery: a randomized study. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association* 3:466-474.
62. Joos AK PP. (2008) Enteral vs parenteral nutrition in reconstructive anal surgery--a prospective-randomized trial. *Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland* 10:605-609.

63. Kang WM YJZ. (2008) Effects of enteral and parenteral nutrition on gastroenteric hormones and gastric motility after subtotal gastrectomy. *Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih / Chinese Academy of Medical Sciences* 23:113-116.
64. Lam NN TNKC. (2008) Early enteral feeding for burned patients--an effective method which should be encouraged in developing countries. *Burns : journal of the International Society for Burn Injuries* 34:192-196.
65. Nagata S F. (2009) Comparison of enteral nutrition with combined enteral and parenteral nutrition in post-pancreaticoduodenectomy patients: a pilot study. *Nutrition Journal* Vol.8, pp.24, 2009..
66. Nguyen NQ FRBLB. (2008) The impact of delaying enteral feeding on gastric emptying, plasma cholecystokinin, and peptide YY concentrations in critically ill patients. *Critical care medicine* 36:1469-1474.
67. Vaithiswaran V. (2008) Effect of early enteral feeding after upper gastrointestinal surgery. *Tropical gastroenterology : official journal of the Digestive Diseases Foundation* 29:91-94.
68. White H. (2009) A randomised controlled comparison of early post-pyloric versus early gastric feeding to meet nutritional targets in ventilated intensive care patients. *Critical care (London, England)* 13:R187, 2009.
69. Elia M and Stratton RJ. (1-6-2008) A cost-utility analysis in patients receiving enteral tube feeding at home and in nursing homes. *Clinical nutrition (Edinburgh, Scotland)* 27:416-423.
70. Silander E, Nyman J, Bove M et al. (2012) Impact of prophylactic percutaneous endoscopic gastrostomy on malnutrition and quality of life in patients with head and neck cancer: a randomized study. *Head & Neck* 34:1-9.
71. Gomes Jr CAR, Lustosa SAS, Matos D et al. (2012) Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances. *Cochrane Database of Systematic Reviews* CD008096.
72. Alagiakrishnan K, Bhanji RA, and Kurian M. (2013) Evaluation and management of oropharyngeal dysphagia in different types of dementia: a systematic review. *Archives of Gerontology & Geriatrics* 56:1-9.
73. Hanson LC, Carey TS, Caprio AJ et al. (2011) Improving decision-making for feeding options in advanced dementia: a randomized, controlled trial. *Journal of the American Geriatrics Society* 59:2009-2016.
74. Pfab F, Winhard M, Nowak-Machen M et al. (2011) Acupuncture in critically ill patients improves delayed gastric emptying: a randomized controlled trial. *Anesthesia & Analgesia* 112:150-155.
75. Cobell WJ, Hinds AM, Lim RG et al. (2013) Feeding after percutaneous endoscopic gastrostomy: Experience of early versus delayed feeding. *Gastrointestinal Endoscopy* 77:AB150-AB151.
76. Doig GS, Chevrou-Severac H, and Simpson F. (2013) Early enteral nutrition in critical illness: a full economic analysis using US costs. *Clinicoecon.Outcomes Res* 5:429-436.
77. Nugent B, Lewis S, and O'Sullivan JM. (2013) Enteral feeding methods for nutritional management in patients with head and neck cancers being treated with radiotherapy and/or chemotherapy. *Cochrane database of systematic reviews (Online)* 1:CD007904.
78. Arefian NM, Teymourian H, and Radpay B. (2007) Effect of partial parenteral versus enteral nutritional therapy on serum indices in multiple trauma patients. *Tanaffos* 6:37-41.

79. Ryu J. (2009) Clinical outcomes comparing parenteral and nasogastric tube nutrition after laryngeal and pharyngeal cancer surgery. *Dysphagia* 24:378-386.
80. Wang Q, Liu ZS, Qian Q et al. (28-8-2008) Treatment of upper gastrointestinal fistula and leakage with personal stage nutrition support. *World Journal of Gastroenterology* 14:5073-5077.
81. Wu XM JKWHLGZ. (2010) Total enteral nutrition in prevention of pancreatic necrotic infection in severe acute pancreatitis. *Pancreas* 39:248-251.
82. Casaer MP, Mesotten D, Hermans G et al. (29-6-2011) Early versus Late Parenteral Nutrition in Critically Ill Adults. *New England Journal of Medicine* 365:506-517.
83. Vincent RP, Omar S, Elnenaei MO et al. (2013) Adherence to the National Institute of Clinical Excellence guidance on parenteral nutrition screening is not enough to improve outcomes. *Clinical nutrition (Edinburgh, Scotland)* 32:73-76.
84. Geeganage C, Beavan J, Ellender S et al. (2012) Interventions for dysphagia and nutritional support in acute and subacute stroke. *Cochrane Database of Systematic Reviews* CD000323.
85. Koretz RL, Avenell A, and Lipman TO. (2012) Nutritional support for liver disease. *Cochrane Database of Systematic Reviews* 5:CD008344.
86. Ney M, Vandermeer B, van Zanten SJV et al. (2013) Meta-analysis: oral or enteral nutritional supplementation in cirrhosis. *Alimentary pharmacology & therapeutics* 37:672-679.
87. Friesecke S L. (2008) Fish oil supplementation in the parenteral nutrition of critically ill medical patients: a randomised controlled trial. *Intensive Care Medicine* 34:1411-1420.
88. Wang X. (2008) Omega-3 fatty acids-supplemented parenteral nutrition decreases hyperinflammatory response and attenuates systemic disease sequelae in severe acute pancreatitis: a randomized and controlled study. *JPEN Journal of parenteral and enteral nutrition.* 32:236-241.
89. Wang X. (2009) Fish oil-supplemented parenteral nutrition in severe acute pancreatitis patients and effects on immune function and infectious risk: a randomized controlled trial. *Inflammation* 32:304-309.
90. Jiang ZM WDWXWJZZGZWSHSJ. (2010) Randomized clinical trial of intravenous soybean oil alone versus soybean oil plus fish oil emulsion after gastrointestinal cancer surgery. *The British journal of surgery* 97:804-809.
91. Piper SN RKB. (2008) Hepatocellular integrity in patients requiring parenteral nutrition: comparison of structured MCT/LCT vs. a standard MCT/LCT emulsion and a LCT emulsion. *European journal of anaesthesiology* 25:557-565.
92. Puiggros C. (2009) Evolution of lipid profile, liver function, and pattern of plasma fatty acids according to the type of lipid emulsion administered in parenteral nutrition in the early postoperative period after digestive surgery. *JPEN Journal of parenteral and enteral nutrition.* 33:501-512.
93. Sun LC, Shih YL, Lu CY et al. (2008) Randomized, controlled study of branched chain amino acid-enriched total parenteral nutrition in malnourished patients with gastrointestinal cancer undergoing surgery. *American Surgeon* 74:237-242.
94. Casas-Rodera P, mez-Candela C, tez S et al. (2008) Immunoenhanced enteral nutrition formulas in head and neck cancer surgery: a prospective, randomized clinical trial. *Nutricion Hospitalaria* 23:105-110.
95. Celik JB GK. (2009) The role of immunonutrition in gynecologic oncologic surgery. *European journal of gynaecological oncology* 30:418-421.

96. Klek S K. (2008) Standard and immunomodulating enteral nutrition in patients after extended gastrointestinal surgery--a prospective, randomized, controlled clinical trial. *Clinical nutrition (Edinburgh, Scotland)* 27:504-512.
97. Pontes-Arruda A. (2006) Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. *Critical care medicine* 34:2325-2333.
98. Qin HL ZJTDCWFXHXJY. (2008) Effect of *Lactobacillus plantarum* enteral feeding on the gut permeability and septic complications in the patients with acute pancreatitis. *European Journal of Clinical Nutrition* 62:923-930.
99. Ryan AM RJH. (2009) Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial. *Annals of surgery* 249:355-363.
100. Slotwinski R, Olszewski WL, Lech G et al. (2008) Immunonutrition after major pancreatic surgery. *Central-European Journal of Immunology* 33:67-73.
101. Theilla M, Singer P, Cohen J et al. (2007) A diet enriched in eicosapentanoic acid, gamma-linolenic acid and antioxidants in the prevention of new pressure ulcer formation in critically ill patients with acute lung injury: A randomized, prospective, controlled study. *Clinical Nutrition* 26:752-757.
102. van Stijn MF BPRML-MGTJD. (2010) Antioxidant-enriched enteral nutrition and immuno-inflammatory response after major gastrointestinal tract surgery. *The British journal of nutrition* 103:314-318.
103. van Stijn MF L-MGBPSPT. (2008) Antioxidant enriched enteral nutrition and oxidative stress after major gastrointestinal tract surgery. *World journal of gastroenterology : WJG* 14:6960-6969.
104. Cereda E G. (2009) Disease-specific, versus standard, nutritional support for the treatment of pressure ulcers in institutionalized older adults: a randomized controlled trial. *Journal of the American Geriatrics Society* 57:1395-1402.
105. Chapman IM, Visvanathan R, Hammond AJ et al. (2009) Effect of testosterone and a nutritional supplement, alone and in combination, on hospital admissions in undernourished older men and women. *American Journal of Clinical Nutrition* 89:880-889.
106. Garbagnati F, Cairella G, De MA et al. (2009) Is antioxidant and n-3 supplementation able to improve functional status in poststroke patients? Results from the Nutristroke Trial. *Cerebrovascular Diseases* 27:375-383.
107. Gunerhan Y. (2009) Effect of preoperative immunonutrition and other nutrition models on cellular immune parameters. *World journal of gastroenterology : WJG* 15:467-472.
108. Langkamp-Henken B. (2006) Nutritional formula improved immune profiles of seniors living in nursing homes. *Journal of the American Geriatrics Society* 54:1861-1870.
109. Schiffrin EJ, Thomas DR, Kumar VB et al. (2007) Systemic inflammatory markers in older persons: the effect of oral nutritional supplementation with prebiotics. *Journal of Nutrition, Health & Aging* 11:475-479.
110. Sorensen D. (2009) Perioperative immunonutrition in head and neck cancer. *The Laryngoscope* 119:1358-1364.
111. Blijlevens NM DJNASADB. (2005) A randomised, double-blinded, placebo-controlled, pilot study of parenteral glutamine for allogeneic stem cell transplant patients. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer* 13:790-796.
112. Buijs N, van Bokhorst-de van der Schueren MA, Langius JA et al. (2010) Perioperative arginine-supplemented nutrition in malnourished patients with head and neck cancer improves long-term survival. *American Journal of Clinical Nutrition* 92:1151-1156.

113. Culkin A. (2008) A double-blind, randomized, controlled crossover trial of glutamine supplementation in home parenteral nutrition. *European Journal of Clinical Nutrition* 62:575-583.
114. da Gama Torres HO VEdCAGESMAAAWLFSABH. (2008) Efficacy of glutamine-supplemented parenteral nutrition on short-term survival following allo-SCT: a randomized study. *Bone marrow transplantation* 41:1021-1027.
115. Estivariz CF GDL. (2008) Efficacy of parenteral nutrition supplemented with glutamine dipeptide to decrease hospital infections in critically ill surgical patients. *JPEN Journal of parenteral and enteral nutrition*. 32:389-402.
116. Fan YP YJKWZ. (2009) Effects of glutamine supplementation on patients undergoing abdominal surgery. *Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih / Chinese Academy of Medical Sciences* 24:55-59.
117. Jo S CSHJKEMMCDJCKY. (2006) Missing effect of glutamine supplementation on the surgical outcome after pancreaticoduodenectomy for periampullary tumors: a prospective, randomized, double-blind, controlled clinical trial. *World Journal of Surgery* 30:1974-1982.
118. Luo M. (2008) Depletion of plasma antioxidants in surgical intensive care unit patients requiring parenteral feeding: effects of parenteral nutrition with or without alanyl-glutamine dipeptide supplementation. *Nutrition (Burbank, Los Angeles County, Calif)* 24:37-44.
119. Luo Y, Xu W-G, Dong H-J et al. (2005) Glutamine for immunomodification and metabolic support in patients with chronic obstructive pulmonary disease. *Chinese Journal of Clinical Rehabilitation* 9:234-236.
120. Tang ZF LYL. (2007) Glutamine and recombinant human growth hormone protect intestinal barrier function following portal hypertension surgery. *World journal of gastroenterology : WJG* 13:2223-2228.
121. Yeh CN LHLYCKHTJYCM. (2008) The role of parenteral glutamine supplement for surgical patient perioperatively: result of a single center, prospective and controlled study. *Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie* 393:849-855.
122. Klek S K. (2008) The impact of immunostimulating nutrition on infectious complications after upper gastrointestinal surgery: a prospective, randomized, clinical trial. *Annals of surgery* 248:212-220.
123. McQuiggan M. (2008) Enteral glutamine during active shock resuscitation is safe and enhances tolerance of enteral feeding. *JPEN Journal of parenteral and enteral nutrition*. 32:28-35.
124. Cereda E G. (2009) Disease-specific, versus standard, nutritional support for the treatment of pressure ulcers in institutionalized older adults: a randomized controlled trial. *Journal of the American Geriatrics Society* 57:1395-1402.
125. Cerantola Y, H++bner M, Grass F et al. (1-1-2011) Immunonutrition in gastrointestinal surgery. *British Journal of Surgery* 98:37-48.
126. Andrews PJ, Avenell A, Noble DW et al. (17-3-2011) Randomised trial of glutamine, selenium, or both, to supplement parenteral nutrition for critically ill patients. *BMJ* 342.
127. Heyland D, Muscedere J, Wischmeyer PE et al. (17-4-2013) A Randomized Trial of Glutamine and Antioxidants in Critically Ill Patients. *New England Journal of Medicine* 368:1489-1497.
128. Vasson MP, Talvas J, Perche O et al. (20-6-2013) Immunonutrition improves functional capacities in head and neck and esophageal cancer patients undergoing radiochemotherapy: A randomized clinical trial. *Clin Nutr* .

129. Zhao H, Wang Y, Jing H et al. (2013) Randomized clinical trial of arginine-supplemented enteral nutrition versus standard enteral nutrition in patients undergoing gastric cancer surgery. *Journal of Cancer Research and Clinical Oncology* 139:1465-1470.
130. Manzanares W, Dhaliwal R, Jurewitsch B et al. (1-1-2014) Parenteral Fish Oil Lipid Emulsions in the Critically Ill: A Systematic Review and Meta-Analysis. *Journal of Parenteral and Enteral Nutrition* 38:20-28.
131. Palmer AJ, Ho CK, Ajibola O et al. (2013) The role of omega-3 fatty acid supplemented parenteral nutrition in critical illness in adults: a systematic review and meta-analysis. *Critical care medicine* 41:307-316.
132. Mocellin MC, Pastore E Silva, Camargo CDQ et al. (2013) Fish oil decreases C-reactive protein/albumin ratio improving nutritional prognosis and plasma fatty acid profile in colorectal cancer patients. *Lipids* 48:879-888.
133. Yeh KY, Wang HM, Chang JW et al. (2013) Omega-3 fatty acid-, micronutrient-, and probiotic-enriched nutrition helps body weight stabilization in head and neck cancer cachexia. *Oral Surg Oral Med Oral Pathol.Oral Radiol* 116:41-48.